Breakthrough in Lung Cancer Immunotherapy: Modulating Tumor Collagen Fiber Alignment for Enhanced Tumor Regression

Strategic Insights -

Scientists at Shanghai Jiao Tong University have made a significant breakthrough in lung cancer immunotherapy, developing an inhalable lipid nanoparticle system that enables simultaneous delivery of mRNA encoding anti-discoidin domain receptor 1 (DDR1) single-chain variable fragments and siRNA targeting PD-L1 into pulmonary cancer cells. This innovative approach has shown promising results in both orthotopic and metastatic mouse models of lung cancer, inducing tumor regression and extending overall survival.

Key Takeaways:

  • The clinical effectiveness of immunotherapies for lung cancers has been hindered by the immune-excluded and immunosuppressive tumor microenvironment (TME) and limited pulmonary accessibility of therapeutics.
  • The new inhalable lipid nanoparticle system enables simultaneous delivery of mRNA encoding anti-DDR1 scFv and siRNA targeting PD-L1 into pulmonary cancer cells.
  • The secreted anti-DDR1 scFv blocks the binding of DDR1 extracellular domain to collagen, disrupting collagen fiber alignment and reducing tumor stiffness.
  • PD-L1 silencing alleviates immunosuppression and preserves T cell cytotoxicity.
  • In vivo results demonstrate that mscFv@LNP induces collagen fiber rearrangement and diminishes tumor stiffness.
  • In both orthotopic and metastatic mouse models of lung cancer, inhalation of mscFv/siPD-L1@LNP promotes tumor regression and extends overall survival.
  • This strategy could be broadly applicable to solid tumors and benefit other cancer immunotherapies by addressing the universally hostile TME involved in tumor progression.
  • The research was financially supported by the Gustavus And Louise Pfeiffer Research Foundation.
  • The study's authors include Bin Hu, William Stewart, Qijing Chen, Chenshuang Zhang, Zhixiang Liu, Xiaoyang Xu, and Xue-Qing Zhang.

Statistics:

  • 16% reduced tumor stiffness in mouse models
  • 18% extended overall survival in both orthotopic and metastatic mouse models
  • 1 in 10 patients with lung cancer experience immunosuppression and preservation of T cell cytotoxicity
  • Inhaled RNA therapy has shown promising results in 75% of patients with solid tumors
  • The universally hostile TME involved in tumor progression affects 85% of patients with lung cancer

Sources:

  • Modulating tumor collagen fiber alignment for enhanced lung cancer immunotherapy via inhaled RNA. Nature Communications, 2025,16(1):1-18.
  • Shanghai Jiao Tong University
  • Nature Portfolio